Drugs / DWC202206
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05643508 | Feb 2023 → Sep 2024 | hyperlipidemia, hypertensive disorder | Daewoong Pharmaceutical Co. LTD. | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DWC202206 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05643508 ↗ |